Success Metrics

Clinical Success Rate
100.0%

Based on 6 completed trials

Completion Rate
100%(6/6)
Active Trials
1(11%)
Results Posted
50%(3 trials)

Phase Distribution

Ph phase_2
5
56%
Ph not_applicable
1
11%
Ph phase_1
1
11%
Ph phase_3
2
22%

Phase Distribution

1

Early Stage

5

Mid Stage

2

Late Stage

Phase Distribution9 total trials
Phase 1Safety & dosage
1(11.1%)
Phase 2Efficacy & side effects
5(55.6%)
Phase 3Large-scale testing
2(22.2%)
N/ANon-phased studies
1(11.1%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

75.0%

6 of 8 finished

Non-Completion Rate

25.0%

2 ended early

Currently Active

1

trials recruiting

Total Trials

9

all time

Status Distribution
Active(1)
Completed(6)
Terminated(2)

Detailed Status

Completed6
Withdrawn2
Recruiting1

Development Timeline

Analytics

Development Status

Total Trials
9
Active
1
Success Rate
100.0%
Most Advanced
Phase 3

Trials by Phase

Phase 11 (11.1%)
Phase 25 (55.6%)
Phase 32 (22.2%)
N/A1 (11.1%)

Trials by Status

withdrawn222%
completed667%
recruiting111%

Recent Activity

1 active trials
Showing 5 of 9
completedphase_1

Study Investigating the Association of NP137 With mFOLFIRINOX in Locally Advanced Pancreatic Ductal Adenocarcinoma

NCT05546853
recruitingphase_2

A Study Evaluating the Efficacy of 5-FU + NALIRI and 5-FU + NALIRINOX for PDAC (NALPAC)

NCT05472259
completedphase_2

Study Comparing Pathological Responses Observed on Colorectal Cancer Metastases Resected After Preoperative Bevacizumab With FOLFOX or FOLFIRI.

NCT01858649
completedphase_3

Active Symptom Control Alone or With mFOLFOX Chemotherapy for Locally Advanced/ Metastatic Biliary Tract Cancers

NCT01926236
completedphase_2

A Study in Advanced Solid Tumors

NCT01063075
View all 9 trials

Clinical Trials (9)

Showing 9 of 9 trials
NCT05546853Phase 1

Study Investigating the Association of NP137 With mFOLFIRINOX in Locally Advanced Pancreatic Ductal Adenocarcinoma

Completed
NCT05472259Phase 2

A Study Evaluating the Efficacy of 5-FU + NALIRI and 5-FU + NALIRINOX for PDAC (NALPAC)

Recruiting
NCT01858649Phase 2

Study Comparing Pathological Responses Observed on Colorectal Cancer Metastases Resected After Preoperative Bevacizumab With FOLFOX or FOLFIRI.

Completed
NCT01926236Phase 3

Active Symptom Control Alone or With mFOLFOX Chemotherapy for Locally Advanced/ Metastatic Biliary Tract Cancers

Completed
NCT01063075Phase 2

A Study in Advanced Solid Tumors

Completed
NCT00577109Phase 2

A Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Patients With Previously Untreated Metastatic Colorectal Cancer.

Withdrawn
NCT00069108Phase 3

A Study of Xeloda (Capecitabine) in Patients With Metastatic Colorectal Cancer

Completed
NCT00448136Phase 2

A Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Patients With Endocrine Tumors of the Gastrointestinal Tract.

Completed
NCT01631539Not Applicable

Chemoembolisation With CPT11 Loaded DC Bead With Cetuximab and 5FU/LV in First Line in Patients With KRAS Wildtype mCRC

Withdrawn

All 9 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
9